Genentech, part of the Roche Group, announced significant results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) with GemOx (R-GemOx) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma…
Today, Vertex announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials involving individuals with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology Association (EHA) Congress, confirm the…
Today, detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) were announced. The study revealed a median OS of 24.6 months (95% CI, 13.4,…
The RNA-biomarker company announced today the appointment of Krista McKerracher as Chairperson of the Board of Directors. McKerracher is a seasoned biopharmaceutical leader with a passion for bringing new medicines to patients with life-threatening diseases. She has nearly three decades…
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the granting of inducement restricted stock units (RSUs) and an option to 15 new employees as part of…
Today, Vertex Pharmaceuticals announced the presentation of new data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), known in the European Union and the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, at the 47th European Cystic Fibrosis Society (ECFS) Conference held June…
Today, Lilly announced that Anat Ashkenazi, the company’s Chief Financial Officer (CFO), has resigned from her position to pursue a career opportunity outside the pharmaceutical industry. David A. Ricks, the Chair and CEO of Lilly, expressed gratitude for Ashkenazi’s 23…
Today, AbbVie announced the first patient has been treated with ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a bispecific antibody T-cell engager targeting BCMA and CD3, featuring high BCMA-avidity and low-affinity CD3 binding domains. The Phase 3, multicenter,…
Shionogi & Co., Ltd. recently announced that its subsidiary, Qpex Biopharma, Inc., has exercised a $10 million option granted by the Biomedical Advanced Research and Development Authority (BARDA). This additional funding, part of an ongoing partnership with BARDA, aims to…
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion, recommending the authorization for two new device presentations of bimekizumab.…
AbbVie announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of risankizumab (SKYRIZI®) for treating adults with moderately to severely active ulcerative colitis (UC) who…
Integrated Biosciences, a biotechnology company leveraging synthetic biology and machine learning to create next-generation therapeutics for age-related diseases, announced its collaboration with Illumina Ventures Labs. This partnership aims to integrate Integrated Biosciences’ drug discovery engine with Illumina sequencing, providing both…